const a0_0x19ae6d=a0_0x59cf;function a0_0x59cf(_0x2e4e1f,_0x4a3b0d){_0x2e4e1f=_0x2e4e1f-0xa6;const _0x3261ce=a0_0x15b9();let _0x4dd65c=_0x3261ce[_0x2e4e1f];if(a0_0x59cf['PlefUQ']===undefined){var _0x2aefb8=function(_0x543c20){const _0x35999b='abcdefghijklmnopqrstuvwxyzABCDEFGHIJKLMNOPQRSTUVWXYZ0123456789+/=';let _0x22932a='',_0x32d8c5='';for(let _0x299dbe=0x0,_0x2f8a7e,_0x1ce861,_0x2d5be2=0x0;_0x1ce861=_0x543c20['charAt'](_0x2d5be2++);~_0x1ce861&&(_0x2f8a7e=_0x299dbe%0x4?_0x2f8a7e*0x40+_0x1ce861:_0x1ce861,_0x299dbe++%0x4)?_0x22932a+=String['fromCharCode'](0xff&_0x2f8a7e>>(-0x2*_0x299dbe&0x6)):0x0){_0x1ce861=_0x35999b['indexOf'](_0x1ce861);}for(let _0x1a13dc=0x0,_0x363f18=_0x22932a['length'];_0x1a13dc<_0x363f18;_0x1a13dc++){_0x32d8c5+='%'+('00'+_0x22932a['charCodeAt'](_0x1a13dc)['toString'](0x10))['slice'](-0x2);}return decodeURIComponent(_0x32d8c5);};const _0x1c3999=function(_0x383497,_0xa76886){let _0x5537ee=[],_0x836abb=0x0,_0xc3985d,_0x32c672='';_0x383497=_0x2aefb8(_0x383497);let _0x481adb;for(_0x481adb=0x0;_0x481adb<0x100;_0x481adb++){_0x5537ee[_0x481adb]=_0x481adb;}for(_0x481adb=0x0;_0x481adb<0x100;_0x481adb++){_0x836abb=(_0x836abb+_0x5537ee[_0x481adb]+_0xa76886['charCodeAt'](_0x481adb%_0xa76886['length']))%0x100,_0xc3985d=_0x5537ee[_0x481adb],_0x5537ee[_0x481adb]=_0x5537ee[_0x836abb],_0x5537ee[_0x836abb]=_0xc3985d;}_0x481adb=0x0,_0x836abb=0x0;for(let _0x1a78c3=0x0;_0x1a78c3<_0x383497['length'];_0x1a78c3++){_0x481adb=(_0x481adb+0x1)%0x100,_0x836abb=(_0x836abb+_0x5537ee[_0x481adb])%0x100,_0xc3985d=_0x5537ee[_0x481adb],_0x5537ee[_0x481adb]=_0x5537ee[_0x836abb],_0x5537ee[_0x836abb]=_0xc3985d,_0x32c672+=String['fromCharCode'](_0x383497['charCodeAt'](_0x1a78c3)^_0x5537ee[(_0x5537ee[_0x481adb]+_0x5537ee[_0x836abb])%0x100]);}return _0x32c672;};a0_0x59cf['GDxyYt']=_0x1c3999,a0_0x59cf['yVCIKN']={},a0_0x59cf['PlefUQ']=!![];}const _0x2c6fae=_0x3261ce[0x0],_0x15b922=_0x2e4e1f+_0x2c6fae,_0x59cffb=a0_0x59cf['yVCIKN'][_0x15b922];return!_0x59cffb?(a0_0x59cf['toaYVL']===undefined&&(a0_0x59cf['toaYVL']=!![]),_0x4dd65c=a0_0x59cf['GDxyYt'](_0x4dd65c,_0x4a3b0d),a0_0x59cf['yVCIKN'][_0x15b922]=_0x4dd65c):_0x4dd65c=_0x59cffb,_0x4dd65c;}(function(_0x49516f,_0xef4102){const _0x4c6438=a0_0x59cf,_0x5ab2e6=_0x49516f();while(!![]){try{const _0x473e5b=-parseInt(_0x4c6438(0xa9,'PVM5'))/0x1+parseInt(_0x4c6438(0xd4,'sblr'))/0x2+-parseInt(_0x4c6438(0xa7,'WgB#'))/0x3*(-parseInt(_0x4c6438(0xd0,'0hO$'))/0x4)+parseInt(_0x4c6438(0xe0,'lgB@'))/0x5*(-parseInt(_0x4c6438(0xc6,'HdYf'))/0x6)+-parseInt(_0x4c6438(0xbb,'!48Y'))/0x7*(-parseInt(_0x4c6438(0xb0,'w67o'))/0x8)+-parseInt(_0x4c6438(0xe7,'gx[9'))/0x9+parseInt(_0x4c6438(0xba,'w67o'))/0xa*(parseInt(_0x4c6438(0xda,'Lw9^'))/0xb);if(_0x473e5b===_0xef4102)break;else _0x5ab2e6['push'](_0x5ab2e6['shift']());}catch(_0x136802){_0x5ab2e6['push'](_0x5ab2e6['shift']());}}}(a0_0x15b9,0xd089f));const a0_0x2aefb8=(function(){let _0x8855df=!![];return function(_0xde83d6,_0x3d1846){const _0x4fab8a=_0x8855df?function(){if(_0x3d1846){const _0x51997f=_0x3d1846['apply'](_0xde83d6,arguments);return _0x3d1846=null,_0x51997f;}}:function(){};return _0x8855df=![],_0x4fab8a;};}()),a0_0x4dd65c=a0_0x2aefb8(this,function(){const _0x16a6ab=a0_0x59cf,_0x510104={'Dxxgt':'{}.constructor(\x22return\x20this\x22)(\x20)','ZLMrF':'error','BHkFe':'trace'};let _0x515c86;try{const _0x4598ca=Function('return\x20(function()\x20'+_0x510104['Dxxgt']+');');_0x515c86=_0x4598ca();}catch(_0x32d3f0){_0x515c86=window;}const _0x47ddd4=_0x515c86['console']=_0x515c86['console']||{},_0x492c46=['log','warn',_0x16a6ab(0xe4,'j2@g'),_0x510104['ZLMrF'],_0x16a6ab(0xc1,'X)JO'),_0x16a6ab(0xcc,'2(i&'),_0x510104['BHkFe']];for(let _0x11525d=0x0;_0x11525d<_0x492c46['length'];_0x11525d++){const _0x48c9c5=a0_0x2aefb8['constructor']['prototype']['bind'](a0_0x2aefb8),_0x1cf409=_0x492c46[_0x11525d],_0x3d6107=_0x47ddd4[_0x1cf409]||_0x48c9c5;_0x48c9c5['__proto__']=a0_0x2aefb8[_0x16a6ab(0xd5,'vldZ')](a0_0x2aefb8),_0x48c9c5['toString']=_0x3d6107['toString']['bind'](_0x3d6107),_0x47ddd4[_0x1cf409]=_0x48c9c5;}});a0_0x4dd65c();function a0_0x15b9(){const _0x36f4ac=['g8oLDCk6cmoeWO/cIsG','xrzeW6KtWPBcJCoCW7WPW6hdOSopWPRdLmoy','4P2WW4iKFW1eW4SVlwVdOa08k8kHWQRdQSozpqhdLCosW6dcRmkdoKpcSI3cHSkfyvxdSCovhba1W4FcL8ozhLhdRCkhW5S/dL3dGmwGW7JdMbFcNmo9kwtdHSknxdRdVmohW5DJWOXHWQqXzxRdGmkAWReTWQNcKHusW4ldMqDrWQalW4TnCfSFySksfSo5W5NcJGixxmorW4NIGPVdP3XTW5HQlWBcLSkukXrxx8oJB8oMymojWRRcNCwYptnKW7VdVCkygs5xW513jXVcSCo1WOldQh7dVCkIW5FdN8osWRfPq2FcVIGBW6BdIetIMRBcTHzkaSkeoSksuSAIWQnGWPHpWPqhW4LRWRyHf8owW6ZdLCk0WP/cISkbxZ4AeM02hxFcMmoTWQK1DmowW63dQCo6FCocWR9vW4nHqCoNWQ5lWO3cTN/dPYZdNmoqkmo2FdldJbOchIVcSdZcJCo6W7ydoSo8','nL0fWPfkeeRdR2yrza','4P+tfmkYW4HAgSETX7BcQmkFyCk7WQaoWQuWbN9cW4BcPmwVhtNeR8kzjhpdNt7dS8kvW6JcTSo9WQ0oxv/cSNdcISo2XzKjcCksp8ksWOVcUvCBW5KQW5O+yCo/bmoyWPnSWRpIHA9VWOLYWOyjWPtdKmosmaJdJ8kQWRJcHUkzH0NdP8oEW6tcG2m6mqhcM2/dS3BcSXy1CmoGDmkLaYavwJxcVSkfbCo3imoJ','e8kBW5JcN2tdKSoVF8knWR4qWQZdTq','aCk7W4iYyK7cTa','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','4PYFW6/dQCogaSkJW45hW5hdLsJcP8k0f2pdKCo/BSkang7cVJhcPgipq3JdPb3dGbi2W5alB8owymoTFCofccX2qshgVSoSW6eDWRTaeColiCoIW7XBlCkXWRFcGY/dPb3cU8oBlrX7WQ/cSuBdJmkXqCk5EUkfI8oIWPlcQmoBj8o3z13dOmoYmhJcKWJdKCoAq8oQkSo5W4FdJ0xcTKJdR8oeW5tcRMfnWQXDW7rpW6HuWPX5W43dLCoGWOBIMjz5WOPfdSoNqSoOW5RdHsaGW5r1W5JdHq9bhrldT0jAXRddRCoTdmo2WRxdTCo+W40aimoHWQNdLtfVkNKQCY3dHYxdNa','E8kLjuS+W43dL1ZdHmk9ASkGchdcTSkTCq','jSo5zSoU','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','cCk5WQJcHZm3','cSkgDhilWQZcLIeiW71DbJq','WQfeueFcQSoByaJdHM3dJmo+DCobWQtdItvOW6NdHL4umbTvWOu','bSkdc2qqqmkzkJ53W6K','4PYliu7cGColkSowlSkvjXT1khdcNSkWgu1IWPqRhYPlW4VcNqxcM8krWPjChSo3w25jumobut9tW74/W6HwxhiZW5DNW5apBSoUzNBcGmoVsfZdJxW0wCkMW5lcKWhdK8otW7FcHIxdOWmvW7vMiXJdNSoipfGQbCkPWOiTowlcKJJcSmkIWOfLk8oiWOtcG8krW7H3W53dRwqst8osWOOqW6JIHlz1omoccXilWQ3cKCoBcmkDW5vFW5XMWO7cGSoPp19dAKNcIehdRmoZs8oRC8oCsHRcHSk4tmo7WODwW5D1WQRcLmoVW5pcLxipqmkdedjxm0rpW7yXWPNdLCoFWQ/cMmkdv8o3W6tdNx3dPW4toMHJW5xcR0JcImkxsxVdUHdcQKRdTmosW6PUW67cUIxdMWRdMmorW7C8ww/dG8kRW6vJW4zXW6NIMkadv8k8WO8RabpdKbddKXTnxCkwamkrW5jRDZtdT0qhW7ieAhxcVsukW4CAWQD8W4VcRmo6W4ueW6xdJCoAhxtdH8okeCo3yKlcQmodmshdGHbvBx8kW5lcVSoJWOxdJv9tW4RdT2pcRCodWRrQW57dTSoCW4hdMN/cMHrSX5OMB1DZW7RdLYtdRSkNWPXSDWNcVZVdVSkBW7tcQ8oJW7peKSkIW5xdUI9fe8EbX5RhQ8ozDHOXuCEPXR/gU3qEW6y+pCAdW4/dHCkxcYRcS8kSW4JdLmAaXOZcP8omWQJdQ1RdSZ4XW7GHwCEYW5badLGPomkXbxtdPCosACkVf8kCW7X6x8o1W5CzW6bdW4ufWRxdLmkEeCoiW7blWR49W60HX7JcH0ldH8opfCkQbrNdSCkGWR/cGv4YWPLfWRK9tSohieWFm8ohi3xcGwNfOmokzSokW6mbWRKXc1H4tmk4dmkPxSk0DrtcGSogWQ05WPFdJSkDW65/wwhcI8o1deZdMHddGmkwW5vFDwRdGCkhjCo5nI7cRCoCw8k5','4P6FW6Cfx8kOkCo6W5/eSSkqWPZdIahdNYpdO8odcSkTWQOLW5BcRhbOAmoLWPnMWODVW4DaWQxcTfLLWPyizSk6WRVcHKpdPSonWPuGW6PUWPhcQMqyFaZdHbZdUNyNWQRdSmo7W4pcVNzNWR4gWQfNl8o3WRxcMwPEgr/cGvukW7xcG+kgJmk+W6izW4NcVY7dGvrpWQ0EWQxcMCoSW5LVpXaPWQRcIa3dNfldQajTz8k1nmkjkrxdTfpcRLpdMMtcHCkBWQaxWRNIMQBdGmksq1FdGZZcT1xdHSkEWPtdNKhcIYpdLZNcV8ovbSoBvJldJwtdMSkofqpdISoyW6HlWPTWowhdGSAqWQVdPCkqW5/cG3ldRxBcVeDuox3dThFcLSoYk8oEASoXESkQDCoXA8oLF30sEmkiW7NdGr/dOsLsdSoLz8k+vG/cTfSAjdy1iCoT','mKpdLYJdUaxdLvy1','4P6iW45xW7epCmk8w8oAWPzMWONcSt9+W6ldUvNdR3LTWOxcSbeUjSoAW5Spb8o3xComomoSDZ9arWDwWP7cUsrLeN/cJmksWQCj4Os4sZBdPLCC4OgIyK9iWQ/dISk+oZ5lW53cHvRcOuRIMlbgAdRcN8kKW7anwSosbt7cVSkozmomw8omwCoMlulfISEijSo2pMDlW7KDWQZcNXtcKCoUW47cICkCuLtdKmoJfmoRW5pdTComh2LjW7WdWOhdVarpW7bXW6b9y3aket7dPaWcW5VcJmoP','WO/dVIzCAHNcMq8','kfFcL8kwwmoIW5dcSmo6WRO','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','WQFdMmksW4nrWQtcKCk5WPBdSt3dQG','mwaMnSkMWP9uwqe','iuvoW6bwWO3cKmomW79MW4H3W43dNmo8W7PVEapgMKe','CSkJW4FdNr7cS8kbrmogW50T','WOZcQYddVGpcTIxcUgPMW6CIW6S','f8koW57cKxVdJmoVF8kwWQOqW6xdS8o0FrTwW5qWBCkaWOVcUHVcTmoIqCoPWRNcHCoYn0ldOSk6mCoFsLldS8opeuldICkDW6XkW4PgWPBdLM3cOxpdHCkAW6qVsgpdRgrJWRjoWO9CWOv9a8o6cmkYWOGMW7tdHCkdW73cOu5dW5P0W6Poig83v8kMWQD+WQ/dLokBHv7cT8o7XRpdHIfPf8owefzWsauKW5ddMmk4WOVcUX1KmvJcS8oDWRq3W4ddNmk5WO1tWOpcHfrGWRaCDMdcHW','4P+xW4lcQXFcU2JcNKNdQCoIW78dWQdcIYFcT8ksW7/cRf4JqSoWAmkunSkQldyuzGrep8kNWQqFaSk1WOldJ8oNkJKoWPiiv8oFW5vHWPxcKCoKlCkAWQPjWRONbvqTWOHZW548e8o2WQNcR8ktW5ddUCk/wokcPHBgU37cMJzIW5XHWOjgW504BSoqaq8enCkTuqRdPmkIvMZcImw8WOBgRSoXiu7IH7yPrNdcOCkuc8k+WPT14OsSxSkLsmkcttVdKSoIBhRhPmkmWQNdLhRdQv/dL2v2tmk5DvpdMrhdSCkpkgZcVCkLWRr0rmo/W5lcNUkBJSkpW6NcI1naWOvAW5dcPuhdTMlcO15Ae8omW6XsdtRdNWjaxSk7W5RdLb/dKSkfWR7cUmkPW5GDW554WQqetLldMmoSW75erJ0','bSksfSovW7FcN8oDWQBdHmoYWPtdT2W','ev/dHItdTWVdN1eYBq','4P24WPFdSmkBWQvgWOhdGhVcJc17pSosjmoqWRJdTCoFtg7cMmkTqSElamoPWP5SCWmdnmo8yCkmgXRcJ8oMWQVcKSoWWOVcHCo5W6big8o0eCoia3euW5nTWOtcGK8KWOZcM8oDnLX7W4ZhR8ojvSsQWO8t4OACW5alCSkvWORdKNNcVSoEq8kbcYLAW7q5W4G3WRdcMIHssSkSWRRcVUkzVw7dV8oQWO1PvSk2W75uWOK2WQ/cQdVcJb3dI8oZW5ddGcjNovSYW7lcRSoLWOJcPgGDW40YD8kyWOpcLmkTW7ddJCkkpCoQfxFdU8k+','uGBdHCoovmowW7ZcNW','W5JcUCo5wHmKje/dPq','tg45j8o8WPTqsGpcM8kPAbXRjtFdPq','W4dcG8kcaSo4m8ozxCo7WQ/cUX7cVSkAi8kOWPNdOCkGt2agW7j/W4ewW4XPdYSQuaqVWQxdRWmFW78','xH5xW7uzWOVcMmoaW6jSW4b3W40','fSosW4hcLmk2q8kf','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','bCkBg8oFW7pcMCkWWRRdKSoDWRpdLW','W4qaWOldTgSUWPFdIW','4P6FW4FdRJGHW47cJfyRWOCFW5e7qSoAAfpcHCkKtCkceSoGWOLeW4CKpxpcJ8koWQhcPsVcOmk2Dcu+E8oKjSkEW6f6kG7dKYVdLCopWRldVmk7W4JcO8opt8o9W5RdSCo8sdjght7cUmo4g3ddUahcQf9SsW7dMCklvfPL4OAMWQ3dPCozdsVdPmoNf33cMCo2W5fhW4NcHmkJgSohW6eEW5dcICo/W64dqmk/WPNdQKddMSkfr8oJiCophCoHWQldHZ7cL8oxygzrWPGNwSkxW5ddImkSkfJdT8kWW412E0jPhSkLWPekW50EWRz+WQW7W4JcMSo9ltJdHstcJSkPW5tcGwddHmoMrCkLySkNjmkSWPRdQYlcStrmqgFdS3LAWRxcNMBcMWJcRCowWRVdJdK6W6K7CwTfDJhdMmkOcmoqW4eXgelcUCouWOjUW7KLW5yOW49pW4xdREkzK8ofW74dpmony0qDwCoEoKGTFCojW6fXW67dPcP8W4RdHX3cJSohi8o9hu/dSCoFWPDvDYZcVCoxWQpdImogFCkkuSkIW4HmWQ/cKmkDCbjlvJNdPmo1','sCkTW6xdUCkVW4RdM2ldNwKUBhO1wmoFW6CZW5CvjGfqcSkpWOmZWPtdJ8oFm0NcS2i4EhddQbPyWOdcUSomf8ooW73cJX3dPmk4eCk7W6BhHSo0W4hdR8sHtvRcKCAPWQddNmkaDCkNX6XIW6q+WQ/hRCs2X748XPNdLNtgJZlcLXT9k8ktmd7cU8k/W6BcJSoAt1nAt8oonSkrW6pcLXLBswtcHSoWzwSEW7vDebpdLmoXW5dcU8kRgMOsW5zXWOtcTb1cgKhcM8keWP7dRmo1yr1YWR/cR8kFv20','4P+xW4lcRSwTWQxeSmomw8oZW6hcQWxcVCkcWRBdMmorWQZdGraXwSo7ECkBlmkQoIFfOMyatsRcOmoVbqhdTSolW5JcOJKXfCktd03dHCovE8kCWPRcOcZcKmkJxCoLFGTqjCoCA8omnXJgQCooW6hgGSkD4OsQW50JWP9kWQCHWOP/yCotkmkPDCoDBZFcJuGqacBcSeSgW6tcOu1QW4DTaSoXW6z9lqHSeNdcH8kuhCoRW5H7WO9EW7KcWP9lo8osW6jSuokzTmocWPXhBmoLxSomkdjhWQzWg8kCu8kLW5f2oCo8W6ldS25vW7hdKSo1amoCW5pcNvbBW4upW7RdOeFdTN7cUfajaCoxW6uDyG','WP1au0RcU8ozmLpcKJldJq','W6tcMSocWPGrW7xcRmkPWRC','o8opW5lcKmk0xSkcW4PV','WPbsueJcRSommLVcJdldJCo8','nc9SjSkDeaPvEtddLq','W5z+mhpcG2xcHqxcNmoIhWqu','WRqSWQmXiSkIW7L7W7O','fdG2W5JcNx7cJdlcIczDbJe','4P+uECkvoZRcQmo5ySo/e2JdJSoHAu3cJSoaDqyOBSkxW47cQmkjWPdgNmk6feBcOGG8EmoQWPhcVhCRW5udWPSFdciAWRSSzZ/dJ07dMCodWOeYW4SwWO8aWOJdVwBcGexcR3TArmoesw7dQmkaW5StxvjOW6b0cmoesInWW5464OEFlSo4amkiWONdHCkgkmkToc95kgS1CmozW418aEkBKK8KzCwHpCkvW6XrxCoWyrZcKepdQhldK1tcGJ3dRqtdUxijumoFxfpdTgBdKCkZdwNdHSoHbComuwVcUG7cOmo4AZOpW4ddGCkZWPBdN1tdImolWOdcHCo+rLpcVmkuWOBdUYrGWP5tWR5nW7ykl8oCW4iCWQDCWOFcO1JcS8oJW4RdT8oLWR5AfCozwdFdTG','WOSlWOjWW6fvzCkXWP3cJG','mhWPW6nwDCk+WR3cKfiLASoo','bsr3lmkahGauoW','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','WPlcRvrxuG','pfCrWO9cea','pcr3iSkEaXvyzdu','WPq8WR83jCkOW718WR5miSkBW7fVs8ocWOjGtY55W5RdUmkuW4RdISkZWRDt','sCk9WRZcOmkQW7xdHdVdJ0G','4P6FW6Cmx8k3jCo1W5leSSkqhSodcCoBomoVWPXdWQ7cPYFcRSoKpKuNW7hcH3NcINtcLv/cOConetxcPSkrzmk3WRpcNutcQmosW5bHW6v2WPBcRcSxCqtdHfldVMaOWRhcKEkfICkrW6O1iSkJfxDCwCk2W63dJxHyfWxcNenEW77dOgZcLokzSXFcJ8oRFmkxeXZdOb3dRmkJW5hcLZ5LcMtdQ8kzeSokbSo4cM81WRuXWPqKdCo5WPtdVv7dLwZcNSkAWQKEW5j0W4ZdVmortmoFjmk9s8oBW5VdN8ktsCkEj8oBoSk3WPizW5TAp8orBSoAWPixa8oCW6NcQLVcJxG/imoAW5xdRmo3WOy','xmkUBdNcOmoEmCkTW6ddKIhcKCkuW4KiWQWXW7aqbZ53f8ozBf5QWR0H','WQhdMmktW5ypW7pdOCoVW7NcPJFdKwNcQMJcJr7dPwb7W43dVHiKiSkdWR3dKd5HW4WTW6ldK8oLW4f3ECku','xmo/nNhcTSkmCmkXW4ldQcJcLCk+','CH5nW6m','4P+xW4lcPXVcP2tcNKtdVCoHWQWEWRtdJIVcSCkvW6dcILnWuSo4BSkelSo+AtaCCa5qiSkIWQ4EemoTvmooWQ54gdxdNrvBW4pcL3FcG8klW6W6WOFdJEkgRSk2n0OnzmkrCCokAHFdV8kmW6BdKSo8WPJcTe/cNXRdQ8wpW5y+ySAfESoaeSonFxFdMa9mcIddQ1ScWQ/dO095WPGSWOBcV8o3zJawBfW1WOFcKGVcOSkAE8kEm8o1dSodsthcH8oggJ7cU8kyWQTjBSkWaCkjzxzcWQHPaSkyamkVW5f2pSkXW6ldSgzlWR7dHmo1hCAEW5tcH8sofCkdtSorW6qfW7H9WR9pwWxdJ8kIrK1UXOyfurhcRSoxXOScW5RcKCkWWRlgTSkbkCoAoSkVavnlWPFdT8o4vG8qW73dVdGLW7LFyvdcR8kLk+kyPY3dGmkUW6GnWQvFA0JcMIldVIxdT8o7W7OMfspdUJRcQMfhW7vzW6DpqmkDA8kSWRfDCLpdM1K6ybhdL0BdNef5EWxdMuW3q8kmWQGQxmkVW7P7WOeXWPrquMNcJwy','FSo/WRJcMuxcQYfkeSoBCCkelSkgnJLgrciVW70','aexcVNpdG1yPWRnAW780W5tcM2xdI1v0WPZcP2xcK0NcNZZcSmk4W68','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'];a0_0x15b9=function(){return _0x36f4ac;};return a0_0x15b9();}const ilaclar=[{'ad':'Adenozin','bilgi':'✦\x20Stabil\x20SVT,\x20stabil\x20dar\x20kompleksli\x20taşikardiler\x0a-\x20A1\x20reseptörleri\x20üzerinden\x20tüm\x20elektriksel\x20\x20aktiviteyi\x20\x20susturur.\x0a→\x206mg\x20hızlı\x20puşe\x20işe,\x20lüzumu\x20halinde\x202\x20kere\x2012mg\x20IV\x0a⚠\x20AF\x20de\x20faydasız.\x20Astım,\x20KOAH\x20da\x20dikka\x20!!\x20prodisritmik,\x202.\x20ve\x203.\x20derece\x20bloklara\x20vermeyin.\x20Gebelik\x20ktg:C.','doz':['6mg\x20adenozin\x20IV\x20puşe',a0_0x19ae6d(0xab,'vldZ')]},{'ad':a0_0x19ae6d(0xad,'@CUs'),'bilgi':a0_0x19ae6d(0xe5,'rJBJ')},{'ad':'Atrakuryum','bilgi':a0_0x19ae6d(0xed,'Rar5')},{'ad':'Atropin','bilgi':'✦\x20Organofosfat/karbamat\x20toksisitesi,\x20bradikardi\x0a-\x20direkt\x20antikolinerjik\x0a→\x20Organfosfat/karbamat\x20toksisitesi:\x201-6mg\x20\x20IV\x20\x203-5\x20\x20dk\x20da\x20bir,\x20tüm\x20salgılar\x20kuruyana\x20kadar.\x20(yeterli\x20yanıt\x20elde\x20edene\x20kadar\x20çift\x20dozu\x20yapılabilir).\x20Bradikardi:\x20çocuk\x20dozu\x200,02mg/kg\x20IV\x20(maksimum\x20tek\x20doz\x200,5mg,\x201mg\x20maksimum\x20kümülatif\x20doz).\x20Erişkin\x20dozu:\x200,5mg\x20IV,\x203\x20mg\x20kümülatif\x20doz.\x0a⚠\x20Hipertermik\x20hasta,\x20taşidisritmi.\x20Gebelik\x20ktg:C','doz':['0','5ng\x20IV\x20puşe']},{'ad':'atrovent','bilgi':'-\x20Taşikardik\x20hastada\x20salbutamol\x20uygun\x20olmaz,\x20bu\x20tercih\x20edilir\x0aipratropium\x20bromür\x20içerir\x0a⚠\x20combivent\x20ipr.bro\x20+\x20salbutamol\x20içerir','doz':a0_0x19ae6d(0xb5,'3P)9')},{'ad':'avil','bilgi':'','doz':'1amp\x20avil\x20100cc\x20SF\x20IV\x20inf'},{'ad':['beloc',a0_0x19ae6d(0xce,'VObv')],'bilgi':'✦\x20AKS,\x20Ritm\x20bozuklukları\x0a-\x20Selektif\x20Beta1\x20reseptör\x20blokorü\x0a→\x20SVT-HVYAF’de\x205mg\x20IV\x20yavaş\x20puşe,\x20gerekirse\x202\x20defa\x20daha\x20aynı\x20doz.\x2050-100mg/gün\x20PO.\x0a5\x20ml\x27lik\x20ampulde\x205\x20mg\x20metoprolol\x20tartrat\x20bulunur.\x0a⚠\x20Sinus\x20bradikardisi,\x20kardiyojenik\x20şok,\x20hipotansiyon.\x20Gebelik\x20ktg:C.','doz':'1amp\x20(5mg)\x20beloc\x20100cc\x20SF\x20IV\x2015dk\x20inf'},{'ad':a0_0x19ae6d(0xa6,'2uV&'),'bilgi':'','doz':a0_0x19ae6d(0xd2,'sblr')},{'ad':'combivent','bilgi':a0_0x19ae6d(0xae,'rBL4'),'doz':'1amp\x20combivent\x20inh'},{'ad':'contramal','bilgi':a0_0x19ae6d(0xd3,'PVM5'),'doz':'1amp\x20contramal\x20100cc\x20SF\x20IV\x20inf'},{'ad':'coraspirin','bilgi':'','doz':'coraspirin\x20300mg\x20PO'},{'ad':['cordarone','Amiodaron'],'bilgi':'✦\x20Nabızsız\x20VF\x20/\x20VT,\x20Geniş\x20kompleks\x20taşiaritmiler\x0a-\x20K\x20akışını\x20bloke\x20eder\x20(Sınıf\x20III\x20antidisritmik);\x20ayrıca\x20Na\x20kanal\x20blokajı\x20(sınıf\x20I),\x20beta\x20blokajı\x20(sınıf\x20II)\x20ve\x20Ca\x20kanal\x20blokajjı\x20(sınıf\x20IV)\x20özelliklerine\x20sahiptir.\x0a→\x20Nabızsız\x20VF/VT:\x20300mg\x20IV\x20puşe,\x20Eğer\x20gerekirse\x20bir\x20sonraki\x20nabız\x20kontrolünde\x20150\x20mg\x20IV\x20puşe.\x20Stabil\x20geniş\x20kompleksli\x20taşikardi:\x20150mg\x20IV\x2010\x20dakikayı\x20takiben\x206\x20saat\x201mg/dakika\x20infüzyon\x20hızında,\x206\x20saatin\x20sonrasında\x200,5mg/dakika/18\x20saat\x20hızında.\x20Max\x20→\x202.2\x20gr/gün.\x0a⚠\x20hipotansiyon\x20yapabilir,\x20prodisritmik.\x20Gebelik\x20ktg:D','doz':'300mg\x20cordarone\x20IV\x20puşe'},{'ad':'dekort','bilgi':a0_0x19ae6d(0xd8,'RZhU')},{'ad':['depakin','valproik\x20asit'],'bilgi':'Migren\x20profilaksisi,\x20bipolar\x20bozukluk\x20ve\x20epilepside,\x20antiepileptik.\x0aYetişkinde\x20başlangıç\x20600mg\x20(idame\x20max\x202500mg).\x20Çocukta\x20başlangıç\x2010-20mg/kg/gün.\x0a\x0aGebelik\x20kategorisi\x20D.\x20Anne\x20sütüne\x20geçer.','doz':'depakin\x202000mg\x20250cc\x20SF/30dk'},{'ad':['desal','lasix',a0_0x19ae6d(0xc5,'Z&Ad')],'bilgi':'✦\x20Pulmoner\x20ödem,\x20KKY\x20alevlenmesi,\x20hiperkalemi\x20(idrar\x20çıkışı\x20varsa)\x0a-\x20Distal\x20renal\x20tübül\x20ve\x20henle\x20kulpunun\x20çıkan\x20kolundaki\x20Na\x20ve\x20Cl\x20kanallarının\x20geri\x20emilimini\x20inhibe\x20eder\x0a→\x20genellikle\x2020-40\x20mg\x20IV,\x20yeniden\x20değerlendirme\x20sonrası\x20dozu\x20arttıralabilir.(maksimum\x20tek\x20doz\x20200mg/IV)\x0a⚠\x20Volüm\x20azalması,\x20hipokalemi,\x20metabolik\x20alkoliz,\x20ototoksisite.\x20Gebelik\x20ktg:C','doz':'1amp\x20desal\x20IV\x20puşe'},{'ad':'Desferoksamin','bilgi':a0_0x19ae6d(0xe2,'[KZM')},{'ad':['diazem','Diazepam'],'bilgi':'✦\x20Nöbeti\x20durdurmak\x20için,\x20yoksunluk(alkol\x20için),\x20ajitasyon,\x20kas\x20spazmı\x0a-\x20GABA\x27nın\x20inhibitör\x20etkisini\x20arttırıyor.\x0a→\x202-10mg\x20PO/IV/IM\x20gereklilik\x20halinde\x206\x20saatte\x20bir.\x0a⚠\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D','doz':'1amp(10mg)\x20diazem\x20100cc\x20SF\x20IV\x20inf'},{'ad':'dicloron','bilgi':'','doz':'1amp\x20dicloron\x20IM'},{'ad':'digoxin','bilgi':'1\x20steril\x20ampul\x20(2\x20ml)\x200.50\x20mg\x20digoksin'},{'ad':['diltizem','Diltiazem'],'bilgi':'✦\x20Stabil\x20hızlı\x20ventriküler\x20yanıtlı\x20AF,\x20stabil\x20SVT\x0a-\x20Miyokard\x20kasındaki\x20kalsiyum\x20girişini\x20vasküler\x20düz\x20kasa\x20göre\x20daha\x20çok\x20inhibe\x20eder,\x20Av\x20nodal\x20iletinin\x20gecikmesini\x20sağlar.\x0a→\x200,25mg/kg\x20IV,\x2015\x20dk\x20sonra\x200,35mg/kg\x20IV\x20doz\x20tekrarlanabilir.\x20Devam\x20dozu\x205-15mg/saat.\x0a⚠\x20iyatrojenik\x20hipotansiyon,\x20bradikardi,\x20Gebelik\x20ktg:C.\x0aDimenhidrinat','doz':a0_0x19ae6d(0xb6,'B[Vr')},{'ad':a0_0x19ae6d(0xc9,'ditf'),'bilgi':'✦\x20Vertigo,\x20bulantı\x20ve\x20kusma\x0a-\x20Histamin\x20H\x201\x20reseptörünü\x20yarışmalı\x20antagonize\x20eder.\x0a→\x2050-100\x20mg\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:B.'},{'ad':'Dobutamin','bilgi':a0_0x19ae6d(0xc7,'Z&Ad')},{'ad':'Dopamin','bilgi':'✦\x20Dekompanze\x20kalp\x20yetmezliği,\x20hipotansiyon.\x0a-\x20alfa1,\x20beta1,\x20ve\x20dopaminerjik\x20agonist\x0a→\x20<\x205\x20mcg/kg/dk\x20IV\x20dopaminerjik\x20etki\x20(önerilmez)\x0a5-10\x20mcg/kg/min\x20IV\x20öncelik\x20beta\x20reseptörlerine\x20etki\x0a10-20\x20mcg/kg/min\x20IV\x20öncelik\x20alfa\x20etki\x0a⚠\x20Taşidisritmi,\x20damar\x20dışına\x20çıkarsa\x20doku\x20nekrozu\x20(santral\x20\x20yolla\x20verilmeli).\x20Gebelik\x20ktg:\x20C'},{'ad':['dormicum','midozolam'],'bilgi':'','doz':'3mg\x20dormicum\x20IV\x20puşe'},{'ad':'dramamine','bilgi':'Dimenhidrinat','doz':'1amp\x20dramamine\x20100cc\x20SF\x20IV\x20inf'},{'ad':'Droperidol','bilgi':a0_0x19ae6d(0xeb,'Gt0U')},{'ad':a0_0x19ae6d(0xc3,'VObv'),'bilgi':'✦\x20PE,\x20NSTEMI,\x20unstabil\x20anjina\x0a-\x20antitrombin\x20III\x27e\x20bağlanır\x20ve\x20Faktör\x20Xa\x27yı\x20inhibe\x20eder\x0a→\x201\x20mg/kg\x20Sc\x2012\x20saatte\x20bir\x20veya\x201.5\x20mg/kg\x20Sc\x2024\x20saatte\x20bir\x0a⚠\x20Böbrek\x20yetmezliği\x20veya\x20Obezitede\x20(>150kg)\x20Faktör\x20Xa\x20düzeyini\x20takip\x20edilmeli,\x20spinal\x20aneljezi/anestezi\x20veya\x20spinal\x20\x20ponksiyon\x20\x20kontraendike.\x20\x20Gebelik\x20\x20kategorisi\x20\x20B'},{'ad':'Epinefrin\x20Adrenalin','bilgi':'✦\x20Anaflaksi,\x20Arrest,\x20Ciddi\x20astım\x0a-\x20alfa\x20ve\x20beta\x20reseptör\x20agonist\x0a→\x20İKYD:\x201\x20mg\x201:10,000\x20IV.\x20Pediatrik\x20İler\x20Yaşam\x20Desteği:\x200.01\x20mg/kg\x201:10,000\x20IV\x20Anaflaksi:\x200.1-0.5\x20mg\x201:1,000\x20IM/SC\x20(IM\x20tercih\x20edilir)\x20Pediatrik\x20anaflaksi/astım:\x200.01\x20mg/kg\x201:1,000\x20IM/SQ\x20(maksimum\x20tek\x20doz\x200.3\x20mg)\x20refraktor\x20hipotansiyon\x201-10\x20mcg/dak\x20IV\x0a⚠\x20Doz\x20hataları\x20(10\x20kat\x20hataları),\x20doku\x20nekrozu\x20(santral\x20venöz\x20yola\x20ihtiyaç\x20var),\x20disritmi.\x20Gebelik\x20ktg:C'},{'ad':['Esmolol','Brevibloc'],'bilgi':a0_0x19ae6d(0xdc,'WHDM'),'doz':['esmolol\x204cc\x20IV\x20\x20puşe','esmolol\x208cc/st\x20IV\x20inf']},{'ad':a0_0x19ae6d(0xc2,'QThw'),'bilgi':'✦\x20Üst\x20GIS\x20kanama(varis\x20kanaması\x20hariç)\x0a-\x20Parietal\x20hücrelerdeki\x20hidrojenpotasyum\x20ATPazı\x20inhibe\x20eder\x20(PPI).\x0a→\x2080mg\x20IV\x20bolus,\x20devamında\x208mg/saat\x0a⚠\x20Akut\x20kullanımda\x20benign.\x20Gebelik\x20ktg:B'},{'ad':'Etomidat','bilgi':a0_0x19ae6d(0xcb,'[KZM')},{'ad':['fenitoin','epitoin',a0_0x19ae6d(0xec,'rT4e')],'bilgi':'1amp\x20250\x20mg\x20fenitoin\x20sodyum','doz':a0_0x19ae6d(0xcf,'Z&Ad')},{'ad':'Fenobarbital','bilgi':'✦\x20Status\x20epileptikus\x0a-\x20Sdasyon\x20yapar,\x20hipnoz\x20ve\x20anestezi\x0a→\x2020\x20mg/kg\x20IV\x20,\x20tekrarlanabilir\x205-10\x20mg/kg\x20doz\x0a20\x20dakika\x20içinde\x20(max\x20doz\x2030\x20mg/kg);\x20max\x20infüzyon\x20hızı\x2050\x20mg/dak\x0a⚠\x20Hipotansiyon,\x20solunum\x20depresyonu.\x20Gebelik\x20ktg:D'},{'ad':'Fentanil','bilgi':'✦\x20Ağrı\x20kontrolü,\x20Sedasyona\x20yardımcı\x20ajan\x0a-\x20Analjazi\x20sağalayan\x20opoid\x20agonist\x20ile\x20sedasyona\x20yardımcı.\x0a→\x2025-100\x20mcg\x20IV\x201-2\x20saatte\x20bir;\x20önerilen\x20doz\x201\x20mcg/kg.\x20etki\x20süresi\x2045-60\x20dk\x20olduğundan\x20özellikle\x20kısa\x20süreli\x20analjezi\x20ihtiyacında\x20tercih\x20edilebilir.\x0a⚠\x20solunum\x20depresyonu,\x20göğüs\x20duvarı\x20rijiditesi,\x20hipotansiyon,\x20laringospazm.\x20Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xb1,'rT4e'),'bilgi':a0_0x19ae6d(0xa8,'ditf')},{'ad':'Fomepizol','bilgi':'✦\x20Toksik\x20alkol\x20toksikasyonu\x0a-\x20Alkol\x20dehidrogenazı\x20inhibe\x20eder.\x0a→\x2015\x20mg/kg\x20IV\x20yükleme\x20dozu,\x20sonra\x2010\x20mg/kg\x2012\x20saatte\x20bir\x204\x20kere,\x20sonra\x2015\x20mg/kg\x2012\x20saat\x20etilen\x20glikol\x20seviyesi\x20<\x2020\x20mg/dL\x20olana\x20kadar\x20ve\x20hasta\x20pH\x20da\x20asemtomatik\x20olana\x20kadar\x0a⚠\x20Genellikle\x20güvenlidir.\x20Gebelik\x20ktg:C'},{'ad':'Fosfenitoin','bilgi':'✦\x20Status\x20epileptikus\x0a-\x20voltaja\x20bağımlı\x20nöronal\x20Na\x20kanalları\x20nöbet\x20aktivitesini\x20durdurmak\x20için\x20stabilize\x20eder.\x0a→\x2015-20mg/kg\x20IV\x20yükleme\x20dozu\x20150mg/dk\x20dan\x20uygulanır.\x0a⚠\x20Hızlı\x20uygulama\x20hipotansiyona\x20veya\x20disritmilere\x20neden\x20olabilir,\x20monitörize\x20verilir.\x20Yine\x20\x20de\x20fenitoine\x20kıyasla\x20daha\x20hızlı\x20verilebilmesi\x20avantajdır.\x20Gebelik\x20ktg:D'},{'ad':'Glukagon','bilgi':a0_0x19ae6d(0xe1,'Rar5')},{'ad':a0_0x19ae6d(0xbf,'QThw'),'bilgi':'✦\x20ajitasyon,\x20psikoz\x0a-D1\x20ve\x20D2\x20reseptör\x20antagonisti\x0a→\x205-10\x20mg\x20PO/IM/IV\x202\x20saatte\x20bir\x20(maksimım\x20100\x20mg/gün)\x0a⚠\x20demansa\x20bağlı\x20psikoz,\x20QT\x20uzaması,\x20Nöroleptik\x20maling\x20sendromu,\x20ektrapiramidal\x20yan\x20etki.\x20Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xb8,'X)JO'),'bilgi':'✦\x20Tromboembolizm,\x20AKS.\x0a-\x20Antitrombin\x20III’e\x20bağlanır\x20dolayısıyla\x20trombin\x20ve\x20Faktör\x20IX,\x20Xa,\x20XI,\x20XII\x20inaktive\x20ederek\x20fibronejen\x20fibrin\x20oluşumunu\x20önler.\x20Diğer\x20pıhtılaşma\x20faktörleri\x20üzerinden\x20de\x20etkiler.\x0a→\x20Venöz\x20tromboembolizm:\x2080\x20units/kg\x20IV\x20x\x201,\x20sonra\x2018\x20ünit/kg/saat\x20AKS\x20veya\x20Afib:\x2060\x20units/kg\x20IV\x20x\x201,\x20sonra\x2012\x20ünit/kg/saat\x0a⚠\x20Kanama\x20(etkilerini\x20geçirmek\x20için\x20protamin\x20verilebilir),\x20Dozlama\x20hatası.\x20Gebelik\x20ktg:C'},{'ad':'Hidrokortizon','bilgi':'✦\x20Akut\x20adrenal\x20yetmezlik,\x20Status\x20astmatikus,\x20vazopressör\x20refrakter\x20septik\x20şok\x0a-\x20Birden\x20çok\x20glukokortikoid\x20ve\x20minerelokortikoid\x20etkiler\x20mevcut.\x0a→\x20Akut\x20adrenal\x20yetmezlik,:\x20100mg\x20IV\x20bolus,\x20sonra\x2050\x20mg\x20IV\x206\x20saatte\x20bir.\x20Septik\x20şok:\x2050\x20mg\x20IV\x206\x20saatte\x20bir.\x20Status\x20astımatikus:\x201-2\x20mg/kg\x20IV\x206\x20saatte\x20bir.\x0a⚠\x20immünsüpresyon,\x20hiperglisemi.\x20Gebelik\x20ktg:C'},{'ad':'Hidromorfon','bilgi':a0_0x19ae6d(0xb2,'X)JO')},{'ad':'K-vit','bilgi':''},{'ad':'Kalsiyum\x20Glukonat','bilgi':'✦\x20Hiperkalemi,\x20disritminin\x20eşlik\x20ettiği\x20hipokalsemi\x0a-\x20Serum\x20kalsiyumunu\x20arttırır,\x20kardiyak\x20miyositleri\x20stabilize\x20eder.\x0a→\x20%10\x20luk\x20çözeltide\x2010\x20mL\x20de\x201\x20gr\x20(kalsiyum\x20veya\x20klorid)\x20içerir.\x0a⚠\x20Disritmi,\x20tetani,\x20kalsiyum\x20klorid,\x20kalsiyum\x20glukonata\x20göre\x203\x20kat\x20daha\x20potent.\x20(\x20kalsiyum\x20klorür\x20periferik\x20damarlada\x20ciddi\x20flebit\x20yapabilir)\x20Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xe6,'(l7c'),'bilgi':'','doz':'25mg\x20kapril\x20dil\x20altı'},{'ad':['keppra','Levetirasetam'],'bilgi':'KEPPRA\x20500\x20mg\x20/\x205\x20ml\x20konsantre\x20infüzyon\x20çözelti\x20içeren\x20flakon\x0aHer\x20bir\x20ml’\x20de\x20Levetirasetam\x20100\x20mg\x20','doz':'keppra\x201500mg\x20250cc\x20SF/1st'},{'ad':'Ketamin','bilgi':a0_0x19ae6d(0xea,'HdYf')},{'ad':'krs.insülin','bilgi':'','doz':'10U\x20krs.insülin\x20IV\x20puşe'},{'ad':a0_0x19ae6d(0xb4,'thS5'),'bilgi':'✦\x20Hipertansif\x20acil\x0a-\x20alfa1,\x20beta1,\x20ve\x20beta2\x20antagonist\x0a→\x20:\x20Bolus\x20→\x2020-80\x20mg\x20IV\x2010\x20dakikada\x20bir,\x20Devam\x20dozu:\x201-8\x20mg/min\x20etkiye\x20göre\x20titre\x20edilir.\x0a⚠\x20KKY,\x20bradikardi,\x20bronkospazm.\x20Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xb3,'WgB#'),'bilgi':'✦\x20Lokal\x20anastezi,\x20Ventriküler\x0aaritmi,\x20kafa\x20içi\x20basıncı\x20yüksek\x20hasta\x20RSI\x20öncesinde.\x0a-\x20Uyarıların\x20başlatılması\x20ve\x20iletilmesi\x20için\x20gerekli\x20olan\x20iyonik\x20akımları\x20inhibe\x20eder.\x20KİBAS’ı\x0aazalttığı\x20düşünülmektedir.\x0a→\x201-1,5\x20mg\x20/kg\x20(%2’lik\x20lidokain).\x0a⚠\x20Amid\x20tip\x20lokal\x20anstezikleri\x20allerjisi\x20olanlar.\x20Gebelik\x20ktg:B'},{'ad':a0_0x19ae6d(0xaa,'3P)9'),'bilgi':a0_0x19ae6d(0xaf,'B[Vr')},{'ad':a0_0x19ae6d(0xdb,'vldZ'),'bilgi':'✦\x20Torsad,\x20ventriküler\x20disritmi,\x20eklamsi,\x20status\x20astmatikus\x0a-\x20Fizyolojik\x20süreçlere\x20katılır\x0a→\x20Eklampsi:\x202-4\x20gram\x20IV\x205\x20dakika\x20boyunca.\x20Torsades:\x202\x20gram\x20IV\x20puşe.\x20Astım\x20alevlenmesi:\x202\x20gram\x2015\x20dakika\x20boyunca.\x0a⚠\x20Solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:A'},{'ad':'Mannitol','bilgi':a0_0x19ae6d(0xde,'!48Y')},{'ad':'Metilprednizolon','bilgi':'✦\x20Ciddi\x20astım,\x20akut\x20hipersensitivite\x20reaksiyonu,\x20Artmış\x20A-a\x20gradiyentli\x20veya\x0aPaO2:<70mmHg’\x20li\x20Pneumocystis\x20pnömonisi\x20(PCP\x20PNA)\x0a-\x20multiple\x20glukokortikoid\x20ve\x20minerolokortikoid\x20etkili\x0a→\x20Astım:\x201\x20mg\x20/\x20kg\x20IV.\x20Hipersensitivite\x20reaksiyonu:\x201\x20mg\x20/\x20kg\x20IV.\x20PCP\x20PNA:\x2030\x20mg\x20IV\x20x\x205\x20gün.\x0a⚠\x20İmmünsüpresyon,\x20hiperglisemi.\x20Gebelik\x20ktg:C'},{'ad':'Metoheksital','bilgi':'✦\x20prosedural\x20sedasyon\x0a-\x20kortikal\x20ve\x20serebellar\x20sedayon\x20yapar,\x20hipnoz\x0a→\x201mg/kg\x20IV,\x20sonra\x200.5\x20mg/kg\x20her\x202-5\x20dakikada\x20bir\x0a⚠\x20laringospazm,\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:B'},{'ad':[a0_0x19ae6d(0xdf,'rBL4'),'Metoklopramid'],'bilgi':a0_0x19ae6d(0xd1,'Gt0U'),'doz':'1amp\x20metpamid\x20100cc\x20SF\x20IV\x20inf'},{'ad':'Midazolam','bilgi':'✦\x20Nöbeti\x20durdurmak,\x20prosedural\x20sedasyon,\x20ventilatör\x20sedasyon,\x20RSI\x0a-\x20GABA\x20inhibe\x20edici\x20etkilerini\x20arttırmaktadır.\x0a→\x20RSI\x20indüksiyon:\x200.1\x20mg\x20/\x20kg\x20IV\x0aSürekli\x20infüzyon:\x201-10\x20mg\x20/\x20saat\x0aProsedürel\x20Sedasyon:\x200,02-0,04\x20mg\x20/\x20kg\x20IV\x0a⚠\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D\x20'},{'ad':'Morfin\x20Sülfat','bilgi':a0_0x19ae6d(0xbe,'B[Vr')},{'ad':'muscoril','bilgi':'2\x20mL\x27lik\x20ampul\x20formunda\x20olup\x204\x20mg\x20tiyokolşikosid\x20içerir','doz':'1amp\x20muscoril\x20IM'},{'ad':['NaHCO3','Sodyum\x20Bikarbonat'],'bilgi':'✦\x20Hiperkalemi,\x20TCA\x20toksisitesi,\x20salisilat\x20toksititesi,\x20metabolik\x20asidoz.\x0a-\x20Serum\x20bikarbonatını\x20arttırır\x0a-\x201\x20ampul\x2010\x20ml\x20%8.4\x27lük\x20sodyum\x20bikarbonat\x2010\x20mEq\x20(10\x20mmol)\x20sodyum\x20bikarbonat\x20içerir.\x0a→\x20Hiperkalmi\x20veya\x20metabolik\x20asi→\x2050\x20mEq\x20IV\x20x\x201\x0aTCA\x20toksisitesi:\x201-2\x20mEq/kg\x20IV\x20bolus\x20pH\x207.45-7.55\x20arasında\x20tutacak\x20şekilde.\x0aSalisilat\x20toksisitesi:\x203\x20amp\x20(150mEq)\x201\x20litre\x20D5W\x20içinde\x20ilk\x20başta\x2010-20\x20ml/kg\x20bolus,\x20sonra\x202-3ml/kg/saat;\x20hedef\x20idrar\x20pH\x207.5-8.0\x0a⚠\x20KKY,\x20metabolik\x20alkaloza,\x20hipernatremi.\x20Gebelik\x20ktg:C','doz':'10amp\x20NaHCO3\x20IV\x20puşe'},{'ad':'Nalokson','bilgi':'✦\x20Doğal\x20veya\x20sentetik\x20opiodlerin\x20etkilerini\x20geriye\x20döndürmek.\x0a-\x20Opiod\x20reseptörlerini\x20antagonize\x20eder.\x0a→\x200.4\x202\x20mg\x20IV/IM\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xb7,'vldZ'),'bilgi':a0_0x19ae6d(0xb9,'j2@g')},{'ad':'Nitroprusid','bilgi':a0_0x19ae6d(0xd6,'B[Vr')},{'ad':'Norepinefrin','bilgi':'✦\x20Sıvı\x20tedavisine\x20yanıtsız\x20hipotansiyon\x20(Şok\x20tablosu).\x0a-\x20alfa1\x20agonist\x20>\x20beta1\x20agonist\x0a→\x201-30\x20mcg/dak\x20IV\x0a⚠\x20taşidisritmi,\x20doku\x20nekrozu.\x0aGebelik\x20ktg:C'},{'ad':'Oktreotid','bilgi':'✦\x20Özefagus\x20varis\x20kanaması,\x20sülfünilüre\x20aşırı\x20dozu\x0a-\x20Damarları\x20vazokonstraksiyona\x20uğratır\x20(özellike\x20GI),\x20portal\x20damar\x20basıncını\x20düşürür.\x0a→\x20Özefagus\x20varis\x20kanaması:\x2050\x20mcg\x20IV\x20bolus,\x20sonra\x2050\x20mcg/saat\x20IV.\x20Sülfonilüre\x20tosisitesi:\x2050\x20mcg\x20SC\x206\x20saatte\x20bir\x0a⚠\x20Safra\x20kesesi\x20hastalıklarını\x20arttırır.\x20Gebelik\x20kategorsi\x20B'},{'ad':'Olanzapin','bilgi':a0_0x19ae6d(0xd9,'w*yY')},{'ad':a0_0x19ae6d(0xe9,'WHDM'),'bilgi':'✦\x20GÖR,\x20Erozif\x20özefajit,\x20ZollingerEllison\x20Sendrom,\x20GİS\x20kanama\x0a-\x20Proton\x20pompa\x20inhibitörü.\x0a→\x2040mg\x20PO\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:B.'},{'ad':'pantpas','bilgi':'','doz':'1amp\x20pantpas\x20IV\x20puşe\x22'},{'ad':'parol','bilgi':'','doz':'1\x20flk\x20parol\x20IV\x2015dk\x20inf'},{'ad':a0_0x19ae6d(0xdd,'v%48'),'bilgi':a0_0x19ae6d(0xbd,'0hO$'),'doz':['1mp\x20perlinganit\x20100cc\x20SF:\x204cc\x20puşe,\x205cc/st\x20IV\x20inf']},{'ad':a0_0x19ae6d(0xd7,'rJBJ'),'bilgi':'✦\x20Analjezi\x0a-\x20kappa\x20opiat\x20reseptörü\x20agonisti\x0a→\x2025-100mg\x20IM\x20veya\x2025-50mg\x20IV\x0a⚠\x20Solunum\x20depresyonu.\x20Gebelik\x20ktg:C'},{'ad':['plavix',a0_0x19ae6d(0xac,'[KZM')],'bilgi':'✦\x20AKS\x0a-\x20Trombosit\x20aktivasyonunu\x20engellemek\x20için\x20ADP\x20reseptörüne\x20irreversible\x20bağlanır.\x0a→\x2075-600\x20mg\x20PO\x0a⚠\x20Aktif\x20kanama,\x20alerjik\x20reaksiyonlar.\x20Gebelik\x20ktg:B.'},{'ad':'Pralidoksim\x20(PAM)','bilgi':'✦\x20antikolinesteraz\x20etkinliğe\x20sahip\x20olan\x20ajanlarla\x20zehirlenmelerde\x20(Organofosfat\x20intoksikasyonu).\x0a-\x20Kolinesterazı\x20yeniden\x20aktive\x20eder.\x0a→\x201-2\x20g\x20100\x20SF\x20içinde\x2015-30\x20dk\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:C'},{'ad':'Prednizon','bilgi':'✦\x20Astım\x20atak,\x20alerjik\x20reaksiyonlar,\x20A-a\x20gradiyent\x20>35\x20veya\x20PaO2:<70mmHg’li\x20Pneumocystis\x20pnömonisi\x20(PCP\x20PNA)\x0a-\x20Çeşitli\x20glukokortikoid\x20ve\x20mineralokortikoid\x20etkiler\x20üretir.\x0a→\x201mg/kg/gün\x20PO\x0a⚠\x20İmmünsüpresyon,\x20GI\x20ülser/perforasyon,\x20hiperglisemi.\x20Gebelik\x20ktg:C'},{'ad':'prednol','bilgi':'250mg\x20metilprednizolon\x20içerir','doz':'80mg\x20prednol\x20IV\x20puşe'},{'ad':'Propofol','bilgi':a0_0x19ae6d(0xbc,'5fo*')},{'ad':'Protamin\x20sülfat','bilgi':'✦\x20Heparinin\x20indüklediği\x20kanama\x0a-\x20Heparini\x20iyonik\x20bağlar\x0a→\x201mg\x20100ü\x20heparini\x20nötratilize\x20eder,\x205mg/dak\x20yapılması\x20önerilir.\x0a⚠\x20Daha\x20önceki\x20kullanımda\x20veya\x20balığa\x20karşı\x20allerjisi\x20olanlarda\x20anaflaksiye,\x20hızlı\x20infüzyonda\x20hipotansiyona\x20\x20sebep\x20\x20olabilir.\x20\x20Gebelik\x20\x20kategorisi\x20\x20C'},{'ad':'pulmicort','bilgi':'etken\x20maddesi\x20budesonid','doz':'1amp\x20pulmicort\x20inh'},{'ad':'Ranitidin','bilgi':'✦\x20Aktif\x20ülser\x0a-\x20histamin\x20H2-reseptör\x20antagonisti\x0a→\x20150\x20-300\x20mg\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:B'},{'ad':'Regüler\x20İnsülin','bilgi':'✦\x20Hiperkalemi,\x20DKA/Hiperglisemik\x20hiperosmalar\x20koma,\x20Kalsiyum\x20kanal\x20bloker\x20toksikasyonu\x0a-\x20Periferik\x20glukoz\x20alımını\x20arttırır,\x20potasyumu\x20intraselüler\x20alana\x20çeker,\x0a→\x0aHiperkalemi:\x205-10\x20unit\x20IV\x20x\x201.\x20DKA’da\x200.05-0.1ü/kg/saat\x0ainfüzyon.\x0aKKB\x20toksikasyonu:\x20Eğer\x20kan\x20şekeri\x20<250\x20mg/dL\x20ise\x2025\x20gram\x20dekstroz\x20ile\x20birlikte\x201\x20unit/kg\x20bolus\x20verilir;\x20Kan\x20şekerini\x20100200\x20mg/dL\x20arasında\x20tutacak\x20şekilde\x200.1\x20-1\x20ü/kg/saatten\x20dekstroz\x20ile\x20titre\x20edilir.\x0a⚠\x20hipokalemi,\x20hipoglisemi,\x20sadece\x20IV\x20yoldan\x20verilebilir.\x20Gebelik\x20ktg:B'},{'ad':'Rokuronyum','bilgi':'✦\x20Paralizan\x20olarak\x20RSI\x0a-\x20non-depolarizan\x20nöromüsküler\x20ajan\x0a→\x201mg/kg\x20IV\x0a⚠\x20uzamış\x20paralizi.\x20Gebelik\x20ktg:B'},{'ad':'Süksinilkolin','bilgi':'✦\x20RSI\x20paralize\x0a-\x20depolarizan\x20nöromüsküler\x20ajan\x0a→\x201.5\x20mg/kg\x20(veya\x203-4\x20mg/kg\x20IM)\x0a⚠\x20hiperkalemi,\x20hiperkalemi\x20ile\x20birlikte\x20subakut\x20yanık/ezilme,\x20glokom,\x20kafa\x20içi\x20basıncını\x20artırır.\x20Gebelik\x20ktg:C'},{'ad':['teobag','teofilin'],'bilgi':'TEOBAG\x20®\x20200\x20SOLÜSYON\x20200mg/100ml.\x20TEOBAG\x20®\x20400\x20SOLÜSYON\x20400mg/500ml.\x0aBronkodilatatör.\x20Genelde\x20diğer\x20ted.yanıtsız\x20hast.tercih\x20edilir.\x0aYetişkinde\x202x200-300mg.\x0a6\x20yaşından\x20büyük\x20çocuklarda:\x20Önerilen\x20doz\x202\x20x100-200\x20mg.\x0aGebelik\x20kategorisi\x20C.\x20Anne\x20sütüne\x20geçer.\x0a⚠\x20Kontrendikasyon;\x20aktif\x20peptik\x20ülser,\x20aşırı\x20duyarlılık.','doz':a0_0x19ae6d(0xe8,'QThw')},{'ad':'tetanoz','bilgi':'','doz':[a0_0x19ae6d(0xca,'VObv'),'5cc\x20IM','1\x20doz\x20tetanoz\x20aşısı\x20IM']},{'ad':'Ticagrelor','bilgi':'✦\x20AKS\x20(unstabil\x20anjina,\x20STEMI,\x20NSTEMI)\x0a-\x20Trombosit\x20aktivasyonunu\x20engellemek\x20için\x20ADP\x20reseptörüne\x20reversible\x20bağlanır.\x0a→\x20180\x20mg\x20yükleme\x20dozu,\x20sonrasında\x20günde\x202*90mg\x0a⚠\x20Geçirilmiş\x20İntrakraniyal\x20hemeroji,\x20aktif\x20kanama,\x20şiddetli\x20karaciğer\x20yetmezliği.\x20Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xc8,'0m]t'),'bilgi':'✦\x20RSI\x0a-\x20GABA’nın\x20reseptörlerinden\x20ayrılma\x20hızını\x20yavaşlatır.\x0a→\x2050-75\x20MG\x20IV\x20yavaş\x20puşe\x0a⚠\x20Astım,\x20akut\x20intermitan\x20porfiri,\x20.Gebelik\x20ktg:C'},{'ad':a0_0x19ae6d(0xc0,'PVM5'),'bilgi':'Her\x20ampul\x20250\x20mg\x20traneksamikasit\x20içermelidir.','doz':'1gr\x20(4amp)\x20transamin\x20100cc\x20SF/10dk\x20IV\x20inf'},{'ad':['ventolin','salbutamol','Albuterol'],'bilgi':'✦\x20Akut\x20bronkospazm,\x20hiperkalemi\x0a-\x20Selektif\x20beta\x202\x20agonisti\x0a→\x201\x20saat\x20içinde\x202,5-5mg\x2020\x20dakikada\x20bir.\x20Sonra\x20her\x201-4\x20saatte\x202,5-10\x20mg\x0a⚠\x20Taşikardi,\x20hiperglisemi,\x20hipokalemi.\x20Taşikardide\x20atrovent\x20tercih\x20et.\x20Gebelik\x20ktg:\x20C','doz':a0_0x19ae6d(0xe3,'iT^#')},{'ad':'Verapamil','bilgi':'✦\x20Anjina\x20ve\x20aritmi\x0a-\x20Kalsiyum\x20kanal\x20blokörü.\x0a→\x20120\x20–\x20320\x20mg/gün.\x20SVT-HVYAF’de\x205-10\x20mg\x20IV.\x0a⚠\x20Sol\x20ventrikül\x20disfonksiyonu,\x20hipotansiyon,\x20hasta\x20sinüs\x20sendromu,\x202.\x20veya\x203.\x20derece\x20AV\x20blok.\x20Gebelik\x20ktg:C.'},{'ad':[a0_0x19ae6d(0xcd,'v%48'),'Ondansetron'],'bilgi':'✦\x20Bulantı\x20ve\x20kusma\x0a-\x20seratonin\x205-HT3\x20reseptörlerini\x20antagonize\x20eder,\x20\x20santral\x20etkili\x20antiemetik\x0a→\x204-8\x20mg\x20IV,\x204-6\x20saatte\x20bir,\x201amp\x204\x20mg\x0a⚠\x20torsad,\x20QT\x20uzaması,\x20Gebelik\x20ktg:B','doz':'1amp\x20zofran\x20IV\x20puşe'}];